Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase – chronic myeloid leukemia
| Autor: | Juliana Capannacci, Newton Key Hokama, Michele Ceccarelli, Paula de Oliveira Montandon Hokama, Fulvio D'Angelo, Letícia Antunes Muniz Ferreira, Célia Regina Nogueira, Luigi Cerulo |
|---|---|
| Přispěvatelé: | Universidade Estadual Paulista (Unesp), Hospital Dr. Amaral Carvalho, Sannio University |
| Rok vydání: | 2018 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities Cancer Research Myeloid Chromosomal translocation Philadelphia chromosome 03 medical and health sciences 0302 clinical medicine imatinib mesylate hemic and lymphatic diseases Biomarkers Tumor medicine Humans Circulating MicroRNA Protein Kinase Inhibitors chronic phase Gene Expression Regulation Leukemic business.industry Gene Expression Profiling leukemia Computational Biology Myeloid leukemia Imatinib gene expression regulation Hematology medicine.disease microRNAs Leukemia medicine.anatomical_structure Imatinib mesylate Oncology 030220 oncology & carcinogenesis Leukemia Myeloid Chronic-Phase Imatinib Mesylate Cancer research myeloid Stem cell Transcriptome business Biomarkers 030215 immunology medicine.drug |
| Zdroj: | Scopus Repositório Institucional da UNESP Universidade Estadual Paulista (UNESP) instacron:UNESP |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Made available in DSpace on 2018-12-11T17:22:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2018-01-01 Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib). A pool of total leukocytes from healthy donors was considered as control group. Expression analyses were performed for 768 miRNAs by RT-qPCR array. Bioinformatic tools were used to identify significant pathways and interaction networks. We found 80 deregulated miRNAs between the groups and, according to bioinformatic analysis, they are involved in different pathways, including molecular mechanisms of cancer. The study allows better understanding of disease molecular behavior, and it is useful for possible monitoring CML treatment and prognostic biomarkers identification. Department of Internal Medical São Paulo State University (UNESP-FMB) Laboratory of Molecular Biology Hospital Dr. Amaral Carvalho Department of Science and Technology Sannio University Department of Internal Medical São Paulo State University (UNESP-FMB) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|